Urolithin A Supplement Reverses Age-Related Immune Decline in Middle-Aged Adults
Four-week trial shows mitophagy inducer urolithin A expands youthful T cells and improves immune metabolism in healthy adults aged 45-70.
Summary
A randomized controlled trial of 50 healthy middle-aged adults found that urolithin A supplementation for just 4 weeks significantly improved immune function. The mitophagy-inducing compound expanded naive-like CD8+ T cells, enhanced cellular energy metabolism, and increased beneficial immune cell populations. Participants taking 1,000mg daily showed improved T cell fatty acid oxidation, increased mitochondrial biogenesis, and better immune cell activation responses. These findings suggest urolithin A could help counteract age-related immune decline and chronic inflammation that contribute to disease susceptibility in aging.
Detailed Summary
Age-related immune decline, characterized by reduced naive T cells and chronic low-grade inflammation, increases vulnerability to infections, cancer, and age-related diseases. This groundbreaking study investigated whether urolithin A, a natural mitophagy inducer derived from pomegranates, could reverse these changes in humans.
Researchers conducted a randomized, double-blind, placebo-controlled trial with 50 healthy adults aged 45-70. Participants received either 1,000mg urolithin A or placebo daily for 28 days. The team analyzed immune cell populations, metabolic function, and inflammatory markers before and after treatment.
The results were striking. Urolithin A significantly expanded naive-like CD8+ T cells by 0.5 percentage points compared to placebo, representing a shift toward more youthful immune profiles. Even more impressive was the 14.7 percentage point increase in CD8+ T cell fatty acid oxidation capacity, indicating enhanced cellular energy metabolism. The supplement also increased beneficial immune populations including CD56dim CD16bright NK cells and nonclassical monocytes, while improving T cell activation responses and monocyte bacterial uptake.
Single-cell RNA sequencing revealed that urolithin A triggered widespread transcriptional changes across immune cell types, modulating inflammation and metabolism pathways. The compound enhanced mitochondrial biogenesis in CD8+ T cells, supporting the hypothesis that improved mitochondrial quality control drives these beneficial effects.
These findings suggest urolithin A could serve as a practical intervention for immune aging, potentially reducing disease risk and improving healthspan. The supplement was well-tolerated with no serious adverse events, supporting its safety profile established in previous trials.
Key Findings
- Urolithin A expanded naive-like CD8+ T cells by 0.5 percentage points in just 4 weeks
- CD8+ T cell fatty acid oxidation capacity increased by 14.7 percentage points
- Enhanced mitochondrial biogenesis and beneficial immune cell populations
- Improved T cell activation responses and monocyte bacterial uptake
- Single-cell analysis revealed widespread anti-inflammatory transcriptional changes
Methodology
Randomized, double-blind, placebo-controlled trial of 50 healthy adults aged 45-70 receiving 1,000mg urolithin A or placebo daily for 28 days. Primary outcomes measured T cell subset changes and immune metabolic remodeling using flow cytometry, functional assays, and single-cell RNA sequencing.
Study Limitations
Short 4-week duration limits assessment of long-term effects. Small sample size (n=50) and healthy participant population may not reflect broader applicability. Functional immune outcomes like vaccine responses or infection resistance were not measured.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.